Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 1 8Phase EARLY_PHASE1 2Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Breast 3Gastrointestinal 2CNS 2Thoracic 1Other neoplasm 1Other hematologic neoplasm 1Other 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Endocrine 1

Conditions

Digestive System Neuroendocrine Tumor G1 1

Interventions

lanreotide 5Octreotide 5Everolimus 4Dexmedetomidine 3Cabergoline 3pasireotide 2Phenoxybenzamine 2Carboplatin 2trametinib 1testosterone enanthate 1surufatinib 1selpercatinib 1pralsetinib 1pegvisomant 1lutetium Lu 177 dotatate 1lenvatinib 1larotrectinib 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1entrectinib 1dabrafenib 1candesartan 1arginyllysine 1anlotinib 1Vitamin D 1Trimethoprim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Magnetic Resonance Spectroscopy × Endocrine × Clear all
NCT06016855 2025-12-17

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Vanderbilt-Ingram Cancer Center

Phase 4 Recruiting
6 enrolled
EndocrineGastrointestinalNETOther neoplasm

Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡